1. Signaling Pathways
  2. Immunology/Inflammation
  3. Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most (clusters of differentiation)CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells[1][2].

Transmembrane Glycoprotein Related Products (137):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-Y1089
    4-Dimethylaminopyridine
    99.96%
    4-Dimethylaminopyridine is an acyl transfer catalyst. 4-Dimethylaminopyridine is used for labeling and analysis of glycoproteins on the surface of living cells. 4-Dimethylaminopyridine reduces dyskinesia attacks.
    4-Dimethylaminopyridine
  • HY-102022
    α-Galactosylceramide
    α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor).
    α-Galactosylceramide
  • HY-P99054
    Tusamitamab
    Inhibitor 99.75%
    Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative).
    Tusamitamab
  • HY-P0168
    Cibinetide
    Agonist 99.06%
    Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.
    Cibinetide
  • HY-157122
    VJDT
    Inhibitor 99.68%
    VJDT is a TREM1 small molecule inhibitor that effectively blocks TREM1 signaling. VJDT inhibits tumor growth and can be used in cancer research.
    VJDT
  • HY-P5425A
    Tetanus Toxin (830–844) TFA
    Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope. This promiscuous CD4+ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4+ T-cell responses in a large part of the human population).
    Tetanus Toxin (830–844) TFA
  • HY-P99409
    Oregovomab
    Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells.
    Oregovomab
  • HY-P5351A
    Hyaluronan-binding peptide, biotin labeled TFA
    Hyaluronan-binding peptide, biotin labeled TFA is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.).
    Hyaluronan-binding peptide, biotin labeled TFA
  • HY-P99208
    Lirilumab
    Inhibitor
    Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
    Lirilumab
  • HY-149898
    HA-CD44 interaction inhibitor 1
    Inhibitor 98.93%
    Antitumor agent-109 (compound 6) is an inhibitor of hyaluronic acid (HY-B0633A) targeting to CD44, as well as an anti-tumor agent. Hyaluronic acid interacts with differentiation cluster 44 (CD44) and is involved in tumor growth and invasion. Antitumor agent-109 inhibits MDA-MB-231 cells with EC50 value of 0.59 μM.
    HA-CD44 interaction inhibitor 1
  • HY-P99160
    Labetuzumab
    Inhibitor 99.59%
    Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy.
    Labetuzumab
  • HY-149897
    HA-CD44 interaction inhibitor 2
    Inhibitor 99.04%
    HA-CD44 interaction inhibitor 2 (compound 5) is an Hyaluronic acid (HA)-CD44 interaction inhibitor that effectively disrupts the integrity of cancer spheroids. HA-CD44 interaction inhibitor 2 also exhibits antiproliferative activity against cancer cells.
    HA-CD44 interaction inhibitor 2
  • HY-P99237
    Sofituzumab
    Inhibitor
    Sofituzumab (MMUC 1206A) is a humanizedized anti-MUC16 recombinant V-kappa antibody.
    Sofituzumab
  • HY-P1242
    NEP(1-40)
    Antagonist 99.40%
    NEP(1-40) is a Nogo-66 receptor (NgR) antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition.
    NEP(1-40)
  • HY-P99129
    Anti-Mouse CD8a Antibody (53-6.7)
    Inhibitor
    Anti-Mouse CD8a Antibody is a anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat.
    Anti-Mouse CD8a Antibody (53-6.7)
  • HY-P990673
    Vandortuzumab
    Inhibitor 99.00%
    Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Vandortuzumab
  • HY-P99363
    Feladilimab
    Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer.
    Feladilimab
  • HY-P99202
    Vibostolimab
    Inhibitor
    Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.
    Vibostolimab
  • HY-147329
    RAGE 229
    99.70%
    RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1).
    RAGE 229
  • HY-128111
    ASN02563583
    Activator 99.21%
    ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases.
    ASN02563583